| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(03)12954-6 |
| P698 | PubMed publication ID | 12686053 |
| P2093 | author name string | Mark Lebwohl | |
| P2860 | cites work | Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 |
| Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial | Q28202251 | ||
| Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides | Q30667754 | ||
| Acitretin in combination with UVB or PUVA. | Q33718597 | ||
| CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris | Q33855058 | ||
| Vitamin D analogs: mechanism of action and therapeutic applications | Q34091646 | ||
| Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. | Q34102999 | ||
| Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus | Q34116785 | ||
| Genetic aspects of psoriasis | Q34291363 | ||
| Anti-TNF therapy and malignancy - a critical review | Q34295380 | ||
| Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment | Q34319316 | ||
| The immunologic basis for the treatment of psoriasis with new biologic agents | Q34470558 | ||
| Searching for the major histocompatibility complex psoriasis susceptibility gene. | Q34619466 | ||
| Biologic therapy for psoriasis: the new therapeutic frontier | Q34645976 | ||
| Psoriasis in Australian twins. | Q34729577 | ||
| The pathophysiology of psoriasis | Q36503535 | ||
| Psoriasis in practice. | Q36503539 | ||
| IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach | Q37378185 | ||
| Characterization of Mononuclear Cell Infiltrates in Psoriatic Lesions | Q40693591 | ||
| Methotrexate in psoriasis: consensus conference | Q41728654 | ||
| Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections | Q41917843 | ||
| Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy | Q41976337 | ||
| Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study | Q42460937 | ||
| Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study | Q42601718 | ||
| Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab | Q42628068 | ||
| Etretinate or cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis | Q43462606 | ||
| Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study | Q43548623 | ||
| Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety | Q43607191 | ||
| Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated | Q44198173 | ||
| Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial | Q47570627 | ||
| Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial | Q47957463 | ||
| Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders | Q49240008 | ||
| A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis | Q50688343 | ||
| Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death | Q50882370 | ||
| Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment | Q51008269 | ||
| Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. | Q52018451 | ||
| Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. | Q52221782 | ||
| Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. | Q52277817 | ||
| Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. | Q52958415 | ||
| Psoriasis remission time at the Dead Sea. | Q53855323 | ||
| Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. | Q53873539 | ||
| Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. | Q54340187 | ||
| RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study | Q56765531 | ||
| Successful treatment of Langerhans'-cell histiocytosis with etanercept | Q60746606 | ||
| Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial | Q67577360 | ||
| Out-patient treatment of psoriasis: short contact and overnight dithranol therapy compared | Q69916873 | ||
| Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis | Q70589903 | ||
| Psoriatic arthritis in psoriatic patients | Q70640451 | ||
| Infectious complications of erythrodermic psoriasis | Q71059215 | ||
| Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis | Q71803269 | ||
| Psoriasis | Q73574043 | ||
| Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity | Q73634473 | ||
| Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate | Q73646416 | ||
| Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions | Q73700287 | ||
| Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis | Q74212695 | ||
| Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial | Q74265787 | ||
| Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody | Q74350027 | ||
| Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis? | Q74361398 | ||
| Infliximab for refractory ulcerative colitis | Q74400737 | ||
| Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis | Q74562007 | ||
| Etanercept-induced subacute cutaneous lupus erythematosus | Q77174829 | ||
| A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis | Q77185203 | ||
| Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) | Q77327737 | ||
| Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis | Q77341367 | ||
| Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept | Q77388655 | ||
| Treatment of longstanding active giant cell arteritis with infliximab: report of four cases | Q77406869 | ||
| Drug-induced systemic lupus erythematosus associated with etanercept therapy | Q77696979 | ||
| Psoriatic arthritis | Q93943064 | ||
| P433 | issue | 9364 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1197-1204 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Psoriasis | |
| P478 | volume | 361 |
| Q37316423 | 'I should have taken that further' - missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed-methods study. |
| Q42703641 | 'New to me': changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed-methods feasibility study. |
| Q35020447 | 'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis |
| Q33867374 | A case of primary biliary cirrhosis complicated by Behçet's disease and palmoplantar pustulosis |
| Q35205458 | A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy. |
| Q24680489 | A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes |
| Q83117029 | A practical approach to screening psoriasis patients for therapy with biologic agents |
| Q28267765 | A promoter sequence variant of ZNF750 is linked with familial psoriasis |
| Q41900885 | A rare association between leukocyte adhesion deficiency type I and psoriasis in humans |
| Q41845458 | A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin |
| Q34280904 | Absence of a human DnaJ protein hTid-1S correlates with aberrant actin cytoskeleton organization in lesional psoriatic skin |
| Q34229494 | Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study |
| Q81354761 | Advances in psoriasis treatment |
| Q90116685 | An Uncommon Presentation of Erythrodermic Psoriasis in a Patient Without a History of Psoriasis |
| Q34944668 | Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece |
| Q36479820 | Antimicrobial peptides in the pathogenesis of psoriasis. |
| Q28482161 | Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis |
| Q47959866 | Association of UCP2 -866 G/A polymorphism with chronic inflammatory diseases |
| Q35777198 | Association of methylentetraydrofolate reductase (MTHFR) 677 C > T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a case-control study |
| Q34620257 | Biologics in the management of psoriasis. |
| Q34351604 | Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece |
| Q41686550 | Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris |
| Q37222674 | Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden |
| Q85932898 | Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept |
| Q35834819 | Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis |
| Q37638886 | Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk |
| Q34502118 | Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab |
| Q59809931 | Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain |
| Q34603580 | Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis |
| Q45924926 | Deletion of the late cornified envelope genes LCE3C and LCE3B is associated with psoriasis in a Chinese population. |
| Q41006435 | Dermal vasculature in psoriasis and psoriasiform dermatitis: a morphometric study |
| Q52806769 | Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data. |
| Q30489747 | Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation |
| Q34236439 | Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders |
| Q36083240 | Disease Severity, Quality of Life, and Psychiatric Morbidity in Patients With Psoriasis With Reference to Sociodemographic, Lifestyle, and Clinical Variables: A Prospective, Cross-Sectional Study From Lahore, Pakistan. |
| Q91650631 | Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study |
| Q33580419 | Effect of Wnt3a on keratinocytes utilizing in vitro and bioinformatics analysis |
| Q34200331 | Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques |
| Q33687980 | Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice |
| Q37561580 | Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study |
| Q40437510 | Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study |
| Q37857668 | Emerging treatments in the management of psoriasis: biological targeting with ustekinumab |
| Q34450544 | Etanercept in psoriasis: the evidence of its therapeutic impact. |
| Q97419363 | Evaluation of Corneal Biomechanical Parameters in Psoriasis Patients: A Controlled Study |
| Q41842495 | Evaluation of intralesional 5% 5-fluorouracil in resistant localized plaque psoriasis |
| Q35866830 | Evolution of Cooperation Patterns in Psoriasis Research: Co-Authorship Network Analysis of Papers in Medline (1942-2013). |
| Q53639312 | Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability. |
| Q39205933 | Expression and functional studies on the noncoding RNA, PRINS. |
| Q35945026 | Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor |
| Q91695550 | Fire needle acupuncture or moxibustion for chronic plaque psoriasis: study protocol for a randomized controlled trial |
| Q35739806 | First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis |
| Q24632537 | Function and regulation of retinoic acid-inducible gene-I |
| Q34747478 | Genetic background of psoriasis |
| Q36247085 | Getting under the skin: the immunogenetics of psoriasis |
| Q26991871 | Global epidemiology of psoriasis: a systematic review of incidence and prevalence |
| Q57705930 | Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study |
| Q37770792 | HIV-associated psoriasis: pathogenesis, clinical features, and management |
| Q45996865 | Heavy water labeling of keratin as a non-invasive biomarker of skin turnover in vivo in rodents and humans. |
| Q38641504 | Homocysteine: A Potential Common Route for Cardiovascular Risk and DNA Methylation in Psoriasis |
| Q88872584 | Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature |
| Q34435158 | Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. |
| Q26995800 | Immunology of psoriasis |
| Q80236699 | Immunopathogenesis of psoriasis |
| Q39756516 | Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris. |
| Q24791666 | In vitro pharmacokinetics of anti-psoriatic fumaric acid esters |
| Q24188256 | Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis |
| Q33575734 | Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways |
| Q37307554 | Infliximab for the treatment of plaque psoriasis. |
| Q34620291 | Infliximab in the treatment of plaque type psoriasis |
| Q81354813 | Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial |
| Q91829705 | Interferon Kappa Is Up-Regulated in Psoriasis and It Up-Regulates Psoriasis-Associated Cytokines in vivo |
| Q99416979 | Investigation of predictors of interest in a brief mindfulness-based intervention and its effects in patients with psoriasis at a rehabilitation clinic (SkinMind): an observational study and randomised controlled trial |
| Q37724124 | Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis |
| Q46701286 | Long-term control of psoriasis is necessary |
| Q88687872 | Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q36429698 | Mechanisms of action of topical corticosteroids in psoriasis |
| Q57947476 | MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2 |
| Q47253178 | MicroRNA-146 and cell trauma downregulate expression of the psoriasis-associated atypical chemokine receptor ACKR2. |
| Q21144444 | MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? |
| Q24669852 | Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions |
| Q41967507 | More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis |
| Q37891799 | NK cells and psoriasis |
| Q24202943 | Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis |
| Q24234945 | Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis |
| Q92027635 | Narrowband UVB treatment induces expression of WNT7B, WNT10B and TCF7L2 in psoriasis skin |
| Q47104370 | Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation |
| Q42158699 | New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis |
| Q34088571 | No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. |
| Q37664478 | Novel immunobiologics for psoriasis |
| Q24187957 | Oral fumaric acid esters for psoriasis |
| Q24198185 | Oral fumaric acid esters for psoriasis |
| Q28066898 | Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments |
| Q36742020 | Pathogenesis and therapy of psoriasis |
| Q90567424 | Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children |
| Q35826385 | Pharmacokinetics of oral fumarates in healthy subjects. |
| Q36402885 | Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. |
| Q54404825 | Polymorphisms of the IL23R gene are associated with psoriasis but not with immunoglobulin A nephropathy in a Hungarian population. |
| Q24598008 | Promising new treatments for psoriasis |
| Q92964054 | Protocol for a case-control diagnostic accuracy study to develop diagnostic criteria for psoriasis in children (DIPSOC study): a multicentre study recruiting in UK paediatric dermatology clinics |
| Q88836318 | Psoriasis |
| Q36869144 | Psoriasis and Staphylococcus aureus skin colonization in Moroccan patients |
| Q37369062 | Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions |
| Q24674984 | Psoriasis pathophysiology: current concepts of pathogenesis |
| Q36985655 | Psoriasis vulgaris and familial cancer risk- a population-based study. |
| Q37318036 | Psoriasis-Specific RNA Isoforms Identified by RNA-Seq Analysis of 173,446 Transcripts |
| Q22306121 | Psoriasis: symptoms, treatments and its impact on quality of life |
| Q21245617 | Quality of life in patients with psoriasis |
| Q33915587 | Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease |
| Q89703997 | Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis |
| Q61796314 | Recent Advances on Microbiota Involvement in the Pathogenesis of Autoimmunity |
| Q35556677 | SRSF1 facilitates cytosolic DNA-induced production of type I interferons recognized by RIG-I. |
| Q41130709 | Significance of Anti-cyclic Citrullinated Peptide Autoantibodies in Immune-mediated Inflammatory Skin Disorders with and without Arthritis |
| Q40402673 | Strategies to improve treatment with efalizumab |
| Q38268954 | Targeting autophagy in skin diseases |
| Q37208475 | The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database |
| Q55555049 | The Role of Forkhead Box Class O3A and SIRT1 Gene Variants in Early-Onset Psoriasis. |
| Q36571349 | The Role of MicroRNAs in Human Diseases |
| Q33803222 | The association between 38 previously reported polymorphisms and psoriasis in a Polish population: High predicative accuracy of a genetic risk score combining 16 loci |
| Q33646654 | The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. |
| Q36661303 | The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. |
| Q59137703 | This Rash Puts You in the ICU |
| Q36154179 | Tissue-engineered skin: bottleneck or breakthrough. |
| Q35519210 | Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN. |
| Q34413204 | Transcriptome classification reveals molecular subtypes in psoriasis |
| Q89920790 | Transglutaminase 3 Reduces the Severity of Psoriasis in Imiquimod-Treated Mouse Skin |
| Q35567825 | Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis |
| Q46026172 | Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation. |
| Q37098135 | Treatment of severe psoriasis with infliximab |
| Q33354097 | Type I interferon: potential therapeutic target for psoriasis? |
| Q33841808 | Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. |
| Q44287414 | Vitamin D controls murine and human plasmacytoid dendritic cell function |
| Q82663598 | [Outcome parameters for use in psoriatic arthritis] |
| Q80268504 | [The educational program for the management of psoriasis vulgaris according to the rules of the Task Force on Dermatological Prevention: current status] |
| Q90094215 | miRNA125b Downregulation: A Review of the Novel Paradigm of Psoriasis Epigenetic Regulation |
Search more.